Hologic, Inc. (HOLX) Holdings Raised by Reilly Financial Advisors LLC

Reilly Financial Advisors LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 3.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 39,430 shares of the medical equipment provider’s stock after purchasing an additional 1,390 shares during the period. Reilly Financial Advisors LLC’s holdings in Hologic were worth $1,616,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Parnassus Investments CA boosted its holdings in shares of Hologic by 3.4% in the second quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock valued at $645,593,000 after buying an additional 535,745 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Hologic by 5.1% in the second quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock valued at $231,085,000 after buying an additional 282,510 shares during the period. Partner Fund Management L.P. boosted its holdings in shares of Hologic by 20.3% in the second quarter. Partner Fund Management L.P. now owns 1,892,703 shares of the medical equipment provider’s stock valued at $75,235,000 after buying an additional 319,846 shares during the period. Sterling Capital Management LLC boosted its holdings in shares of Hologic by 1.2% in the second quarter. Sterling Capital Management LLC now owns 1,482,563 shares of the medical equipment provider’s stock valued at $58,932,000 after buying an additional 18,120 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Hologic by 2.4% in the first quarter. Legal & General Group Plc now owns 1,421,810 shares of the medical equipment provider’s stock valued at $53,122,000 after buying an additional 33,131 shares during the period. 98.84% of the stock is owned by hedge funds and other institutional investors.

Several brokerages recently commented on HOLX. Needham & Company LLC increased their target price on shares of Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. BidaskClub upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Wednesday, August 1st. Deutsche Bank increased their target price on shares of Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a report on Wednesday, August 1st. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Bank of America increased their target price on shares of Hologic from $44.00 to $47.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $44.47.

In other news, Director Christiana Stamoulis sold 30,967 shares of the stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $40.70, for a total value of $1,260,356.90. Following the transaction, the director now directly owns 66,006 shares of the company’s stock, valued at $2,686,444.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the stock in a transaction dated Wednesday, September 19th. The shares were sold at an average price of $41.50, for a total transaction of $142,635.50. Following the completion of the transaction, the insider now directly owns 16,520 shares in the company, valued at $685,580. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,661 shares of company stock valued at $1,927,174. Corporate insiders own 0.79% of the company’s stock.

HOLX stock traded down $0.10 during trading hours on Friday, reaching $41.00. The stock had a trading volume of 66,079 shares, compared to its average volume of 1,719,229. The stock has a market cap of $11.32 billion, a P/E ratio of 20.29, a P/E/G ratio of 1.89 and a beta of 0.67. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.29 and a quick ratio of 0.99. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $45.09.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.02. The firm had revenue of $824.00 million during the quarter, compared to analysts’ expectations of $800.14 million. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. As a group, equities research analysts anticipate that Hologic, Inc. will post 2.24 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: What is a conference call?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply